NCT06942377View on ClinicalTrials.gov

Calcium Channel Blocker Amlodipine for Endometrial Cancer Therapy

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

140

Participants

Timeline

Start Date

July 15, 2025

Primary Completion Date

January 1, 2027

Study Completion Date

December 1, 2027

Conditions

Endometrial Cancer

Interventions

DRUG

Amlodipine

Progesterone regimen (oral medroxyprogesterone acetate tablet 250mg-500mg/ day or Mirena +GnRHa3.75mg subcutaneous injection monthly) combined with Amlodipine

Trial Locations (1)

100044

Peking University People's Hospital, Beijing

All Listed Sponsors

lead

Peking University People's Hospital

OTHER